In the preceding three months, 7 analysts have released ratings for Avidity Biosciences (NASDAQ:RNA), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.14, a high estimate of $60.00, and a low estimate of $35.00. Witnessing a positive shift, the current average has risen by 20.87% from the previous average price target of $39.00.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining...
Login or create a forever free account to read this news
Sign up/Log in
